Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharming Group ( (PHAR) ) just unveiled an update.
On October 20, 2025, Pharming Group announced that 12 abstracts were accepted for presentation at the upcoming ACAAI 2025 Annual Scientific Meeting in Orlando, Florida, scheduled for November 6-10. The presentations will showcase new clinical, economic, and comparative data for RUCONEST® in hereditary angioedema (HAE) treatment and real-world effectiveness of Joenja® in treating activated phosphoinositide 3-kinase delta syndrome (APDS). This announcement highlights Pharming’s commitment to advancing patient care and strengthening its position in the rare disease market.
The most recent analyst rating on (PHAR) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall stock score is driven by strong technical analysis and positive earnings call sentiment, indicating potential growth. However, financial performance challenges, particularly in profitability and valuation, weigh down the score. The company’s stable balance sheet and cash flow improvements provide a foundation for future growth if profitability can be enhanced.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a biotechnology company based in the Netherlands, specializing in the development and commercialization of innovative protein replacement therapies for the treatment of rare diseases. Their primary products include RUCONEST®, a recombinant C1 esterase inhibitor for hereditary angioedema (HAE), and Joenja® (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS). The company focuses on addressing unmet medical needs in the rare disease market.
Average Trading Volume: 12,582
Technical Sentiment Signal: Buy
Current Market Cap: $945M
For an in-depth examination of PHAR stock, go to TipRanks’ Overview page.